

## MANNKIND CORP

### FORM 8-K (Current report filing)

## Filed 03/17/17 for the Period Ending 03/16/17

Address 25134 RYE CANYON LOOP

SUITE 300

VALENCIA, CA 91355

Telephone 6617755300

CIK 0000899460

Symbol MNKD

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Medical Research

Sector Healthcare

Fiscal Year 12/31



# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

<b>FORM</b>	8-K
-------------	-----

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2017

## **MannKind Corporation**

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 000-50865 (Commission File Number) 13-3607736 (IRS Employer Identification No.)

25134 Rye Canyon Loop, Suite 300 Valencia, California (Address of principal executive offices)

91355 (Zip Code)

Registrant's telephone number, including area code: (661) 775-5300

N/A

 $(Former\ name\ or\ former\ address, if\ changed\ since\ last\ report.)$ 

ck the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions General Instruction A.2. of Form 8-K):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 □ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01 Other Events.

On March 16, 2017, MannKind Corporation (the "Company") received a letter from the The Nasdaq Stock Market indicating that the Company had regained compliance with the \$1.00 minimum closing bid price requirement.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 17, 2017 MANNKIND CORPORATION

By: /s/ David Thomson

David Thomson, Ph.D., J.D. Corporate Vice President, General Counsel and Secretary